Small-scale study of once-daily oral drug demonstrates sustained biomarker suppression and improvement in motor and non-motor symptoms.
US biotech Ventyx Biosciences has reported encouraging top-line results from a Phase 2a study of its NLRP3 inhibitor in patients with early-stage Parkinson’s disease. While the primary focus was to assess safety and tolerability, the trial also yielded positive data on the drug’s pharmacokinetics, pharmacodynamics and clinical effects.
The small-scale, open-label study enrolled ten patients who received a daily 40 mg dose of Ventyx’s drug, VTX3232, an orally administered, brain-penetrant inhibitor of the NLRP3 inflammasome, over a 28 day period. The trial found that VTX3232 achieved sustained concentrations in both plasma and cerebrospinal fluid that exceeded the level needed to substantially inhibit key pro-inflammatory cytokines. The close alignment of drug exposure in plasma and CSF with findings from earlier studies in healthy volunteers suggests consistent pharmacological behavior and supports its potential as a once-daily treatment for neurodegenerative conditions.
“We are thrilled that our Phase 2a data show that a once-daily dose of VTX3232 can safely maintain plasma and CSF levels above the IC90 for IL-1b for 24 hours in patients with early Parkinson’s disease,” said Ventyx Chief Medical Officer Dr Mark Forman. “In addition, we observed biomarker changes in CSF and plasma that reflect potent NLRP3 inhibition by VTX3232.”
According to Ventyx, the trial demonstrated clear evidence of NLRP3 inhibition, with marked reductions in both primary and secondary biomarkers. Levels of key indicators of NLRP3 activation, declined in both plasma and CSF, while inflammatory markers downstream of the inflammasome, also showed consistent suppression, in some instances approaching the threshold of quantification.
“This was a thorough and well-conducted trial demonstrating clear evidence of target engagement in the CSF and plasma, with significant reduction to near-normal levels or the limit of quantitation (LOQ) in downstream biomarkers of NLRP3 inhibition, including IL-1b, IL-6 and high-sensitivity C-reactive protein (hsCRP),” said the trial’s principal investigator, David Russell of Yale University’s Parkinson’s Disease Research Group.
Clinically, patients receiving VTX3232 experienced statistically significant improvements across multiple domains of Parkinson’s disease symptomatology as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale. These observations suggest that inhibition of the NLRP3 pathway may translate into symptomatic benefit, although further validation in controlled studies is warranted given the trial’s open-label design and small sample size.
With the trial results meeting its internal development criteria, Ventyx is now planning a larger, placebo-controlled Phase 2 trial to further investigate VTX3232 in Parkinson’s disease, while also evaluating the potential for broader application in neurodegenerative conditions such as Alzheimer’s disease. The company’s progress will no doubt please pharma giant Sanofi, which holds a right of first negotiation on VTX3232 following a strategic $27 million investment in 2024.
